Clinical trials: Asthma, Allergic
Asthma
Efficacy and Safety of Four Escalating Dose Regimens of TPI ASM8 in Patients With Allergic Asthma
During this proposed clinical trial, the investigators intend to evaluate the pharmacodynamic anti-inflammatory properties and safety of TPI ASM8, by investigating the effect on sputum eosinophils and the airway responses during…
- Trial name
- NCT00822861
- Testing
- TPI ASM8
- Where
- Canada
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Syntara
Asthma
SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild Asthma
To compare the effects of formoterol alone (Oxis® TurbuhalerÒ) and the fixed combination of formoterol and budesonide (Symbicort® TurbuhalerÒ) on airway responsiveness as a marker of inflammation, induced by repeated low-dose…
- Trial name
- NCT00288379
- Testing
- formoterol, budesonide/formoterol
- Where
- Sweden
- Volunteers
- 16 people
- Sponsor
- AstraZeneca
Allergic Asthma
Effects of AER 001 Administered by Nebulization on Antigen Challenge in Atopic Asthmatics
This is a single centre, double-blind, randomised, parallel group, repeated dose asthmatic subjects. Subjects will receive AER 001 (60 mgs) or placebo twice daily for 28 days.
- Trial name
- NCT00535431
- Testing
- AER 001
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- Aerovance, Inc.
Cat Allergy, Mild Asthma
Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge
The primary objective is to evaluate the prophylactic efficacy of REGN1908-1909 (anti-Fel d 1) administered as a single dose on day 1 in cat-allergic asthmatic patients not living with a cat in the prevention of a Controlled Cat…
- Trial name
- NCT03838731
- Testing
- REGN1908-1909
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Regeneron Pharmaceuticals
Rhinitis, Allergic, Rhinoconjunctivitis, Allergic
HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human
The aim of this first-in-human phase I study is to assess the safety and tolerability of HAL-MRE1 subcutaneous immunotherapy in subjects suffering from ragweed pollen-induced allergic rhinitis/rhinoconjunctivitis with or without…
- Trial name
- NCT03758456
- Testing
- HAL-MRE1
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- HAL Allergy
Asthma
Multiple Dose ASM8 in Mild Asthmatics
To determine the safety and efficacy of multiple doses of ASM8 antisense oligonucleotides in asthmatics.
- Trial name
- NCT00264966
- Testing
- ASM8
- Where
- 3 sites in Canada
- Volunteers
- 15 people
- Sponsor
- Syntara
Asthma
Safety, Tolerability, and Pharmacokinetics After a Single Dose of Orally Inhaled DNAzyme Solution for Nebulisation in Male Patients With Asthma
Asthma is a chronic inflammatory bronchial disorder with three distinct components: airway hyper-responsiveness (respiratory hypersensitivity), airway inflammation, and intermittent airway obstruction.
- Trial name
- NCT01577953
- Testing
- SB010
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Sterna Biologicals GmbH & Co. KG
Asthma, Mastocytosis
Mast Cell Activation Test in Allergic Disease
Activation of mast cells in the immune system is known to cause allergic reactions sometimes with severe systemic symptoms. The investigators have recently developed a blood-based mast cell activation diagnostic test in which…
- Conditions
- Asthma, Mastocytosis, Mast Cell Activation Syndrome, Food Allergy
- Trial name
- NCT03406325
- Where
- Hong Kong
- Volunteers
- 19 people
- Sponsor
- Hong Kong Sanatorium & Hospital
Allergic Rhinitis Due to Dermatophagoides Farinae, Allergic Rhinitis Due to Dermatophagoides Pteronyssinus
House Dust Mite Allergy Trial In Children
A research study of how house dust mite tablets work compared to placebo in children aged between 5 and 11 years and who have allergy to house dust mites (MATIC)
- Conditions
- Allergic Rhinitis Due to Dermatophagoides Farinae, Allergic Rhinitis Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite
- Trial name
- MATIC (NCT04145219)
- Testing
- Sublingual allergy immunotherapy tablet
- Where
- 113 sites in United States, Bulgaria and 9 more
- Volunteers
- 1,460 people
- Sponsor
- ALK-Abelló A/S
Allergic Asthma
Subcutaneous-Sublingual Immunotherapy With Depigmented and Polymerized Dermatophagoides Pteronyssinus Allergen Extract
The objective of this trial is to evaluate the clinical effectiveness of the administration of a depigmented and polymerized allergen extract Dermatophagoides pteronyssinus in children with allergic asthma due to this mite
- Trial name
- NCT00622362
- Testing
- DEPIGOID Dermatophagoides pteronyssinus, Polymerized TOL of Dermatophagoides pteronyssinus
- Where
- Spain
- Volunteers
- 3 people
- Sponsor
- Laboratorios Leti, S.L.
Asthma, Allergic Rhinitis
A Study to Compare Effectiveness of Montelukast Sodium With Comparator in Mild to Moderate Persistent Asthmatics (0476-329)
Subjects have 8-week with montelukast sodium or comparator drug administration period, 2-week wash-out period and 8-week comparator drug or the drug administration period (with cross-over design) for assessment of the drug…
- Trial name
- NCT00157937
- Testing
- MK0476; montelukast sodium/Duration of Treatment: 16 weeks, Comparator: theophylline ER/Duration of Treatment: 16 weeks
- Volunteers
- 31 people
- Sponsor
- Organon and Co
Rhinitis, Allergic, Rhinoconjunctivitis
Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen
Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjunctivitis with or without mild to…
- Conditions
- Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
- Trial name
- NCT04891237
- Testing
- 10,000 MG01 + 10,000 T517, 30,000 MG01 + 10,000 T517
- Where
- 32 sites in Spain
- Volunteers
- 180 people
- Sponsor
- Inmunotek S.L.
Eosinophilic Esophagitis
Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial
This is a randomized, double-blind, placebo-controlled study of APT-1011, followed by an open-label extension (OLE) in adolescents (≥12 to <18 years) with EoE.
- Trial name
- FLUTEEN (NCT05083312)
- Testing
- APT-1011
- Where
- 3 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- Ellodi Pharmaceuticals, LP
Allergic Asthma
Extracorporeal SPecific IgE Removal From the Plasma of Allergic Asthma Patients (ESPIRA-study)
In this study patients suffering from Immunoglobulin E (IgE) mediated asthma are treated with a method, called immune apheresis, that removes IgE from blood.
- Trial name
- ESPIRA (NCT02096237)
- Testing
- IgE adsorber
- Where
- Austria
- Volunteers
- 14 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Allergic Bronchial Asthma
CYT003-QbG10 for Treatment of Allergic Asthma Bronchial
The purpose of the study is to test whether treatment with CYT003-QbG10 can improve asthma symptoms in patients with allergic bronchial asthma. The active treatment will be compared against placebo.
- Trial name
- NCT00890734
- Testing
- CYT003-QbG10
- Where
- Germany
- Volunteers
- 63 people
- Sponsor
- Cytos Biotechnology AG
Allergic Asthma
A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma
This was a multicenter, randomized, double-blind, parallel-group, three-arm, placebo-controlled study designed to demonstrate the efficacy of two different formulations of omalizumab compared with placebo in reducing the airway…
- Trial name
- AQUA (NCT00434434)
- Testing
- omalizumab
- Volunteers
- 61 people
- Sponsor
- Genentech, Inc.
Bronchial Asthma
An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma
This is a randomized, double-blind, comparative, parallel-group study of the efficacy and safety of Genolar® and Xolair® in the treatment of persistent atopic bronchial asthma of moderate and severe course, whose symptoms are…
- Trial name
- NAP (NCT04607629)
- Testing
- Genolar® + Symbicort®, Xolair® + Symbicort®
- Where
- 24 sites in Russia
- Volunteers
- 192 people
- Sponsor
- AO GENERIUM
Asthma
A Bronchoprovocation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic Asthma
This is a non-confirmatory, randomized, subject and investigator blinded, placebo-controlled, parallel-design, multi-center bronchoprovocation study.
- Trial name
- NCT03138811
- Testing
- CSJ117
- Where
- 10 sites in Canada, Germany
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Allergy, Allergic Asthma
abioSCOPE IgE Assay to Aid in the Diagnosis of Allergies
This is a multicenter, prospective, observational study designed to determine the clinical sensitivity and specificity of the Abionic IVD CAPSULE Allergic Asthma panel performed on Abionic's abioSCOPE device using K3-EDTA…
- Conditions
- Allergy, Allergic Asthma, Allergy to Cats, Allergy to House Dust
- Trial name
- NCT04442932
- Testing
- Blood Collection
- Where
- 5 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Abionic SA
Atopic Dermatitis, Asthma
Probiotics and Allergic Diseases
Many studies had demonstrated that probiotics could be applied in the prevention and adjuvant treatment for allergic diseases. In this study, we investigate the effects of Lactobacillus paracasei GMNL-133(LP), Lactobacillus…
- Trial name
- probiotics (NCT01635738)
- Testing
- LP GMNL-133 capsule, LF GM-090 capsule, LP GMNL-133 +LF GM-090 capsule
- Where
- Taiwan
- Volunteers
- 240 people
- Sponsor
- GenMont Biotech Incorporation